Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$413K Sell
6,139
-442
-7% -$29.4K 0.02% 698
2026
Q1
$413K Buy
6,581
+748
+13% +$52.1K 0.02% 629
2025
Q4
$387K Buy
5,833
+2,793
+92% +$181K 0.02% 646
2025
Q3
$205K Sell
3,040
-440
-13% -$34.8K 0.01% 777
2025
Q2
$304K Sell
3,480
-1,468
-30% -$115K 0.02% 541
2025
Q1
$338K Buy
4,948
+2
+0% +$163 0.03% 390
2024
Q4
$385K Buy
4,946
+1,663
+51% +$123K 0.03% 343
2024
Q3
$220K Sell
3,283
-1,605
-33% -$132K 0.02% 424
2024
Q2
$554K Buy
4,888
+112
+2% +$14.2K 0.05% 243
2024
Q1
$662K Buy
4,776
+227
+5% +$28.5K 0.06% 219
2023
Q4
$564K Buy
4,549
+401
+10% +$41K 0.06% 231
2023
Q3
$387K Buy
+4,148
New +$468K 0.05% 227

Other funds holding DXCM

Syon Capital's DXCM Position: Q2 2026 in Review

Syon Capital reduced its DexCom (DXCM) stake by 6.7% in Q2 2026, selling an estimated $29.4K and leaving 6,139 shares worth $413K. The position accounts for 0.02% of the portfolio, ranked #698.

Syon Capital first reported a position in DXCM in Q3 2023 and has held it in 12 quarters since. The position peaked at $662K in Q1 2024. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Syon Capital held 6,139 shares of DexCom worth $413K as of Q2 2026.
  • Syon Capital sold 442 DexCom shares in Q2 2026, an estimated $29.4K.
  • DexCom made up 0.02% of Syon Capital's portfolio in Q2 2026, its #698 holding.
  • Syon Capital first reported a position in DexCom in Q3 2023 and has held it in 12 quarters since.
  • Syon Capital's DexCom position peaked at $662K in Q1 2024.
  • 974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.